Lunit to Implement AI-Powered Chest Screening Solution in Five Major Saudi Hospitals
- Lunit brings Lunit INSIGHT CXR to five major Saudi hospitals, aiming to enhance early detection of common lung abnormalities and improve patient outcomes in line with the national health strategy SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of ...
Lunit Secures $150 Million in Capital Increase
* Fund fully paid-in as of November 9, achieving over 100% shareholder participation SEOUL, South Korea, Nov. 15, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the successful completion of a signi...
Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT
- Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT market SEOUL, South Korea, Nov. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced that it has received U.S....
Lunit, a Founding Member of CancerX, Showcased in the Inaugural Project to Improve Equity and Reduce Financial Toxicity in Cancer Care
- Lunit INSIGHT suite, Lunit's AI-driven solutions for early detection of cancer, featured in CancerX's first official project: enhancing equity and reducing financial burden in cancer care SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered ...
Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023
* Two oral presentations and five ePosters accepted by the RSNA: presenting AI advancements for chest radiograph reporting efficiency and breast cancer risk assessment SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer ...
AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023
* Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment are to be showcased at the SITC 2023 Annual Meeting SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therap...
Lunit Joins as an Associate Partner with the World Economic Forum
- Lunit joins as an Associate Partner of the World Economic Forum, propelling global expansion and collaboration in the realm of AI-driven cancer care SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and th...
Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy
- Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembrolizumab treatment response SEOUL, South Korea, Oct. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
Lunit Participates in Saudi Vision 2030 Healthcare Sandbox, Accelerating Saudi Arabia's Healthcare Transformation
* Memorandum of Understanding to be inked between Lunit and Seha Virtual Hospital, marking a new era inSaudi Arabia's healthcare innovation movement SEOUL, South Korea, Oct. 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and th...
First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO
* Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in theJournal of Clinical Oncology and accepted by ESMO for oral presentation SEOUL, South Korea, Oct. 24, 2023 /PRNewswir...
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023
- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeut...
Lunit to Showcase 9 AI-based Research Results at ESMO 2023
- 9 abstracts accepted by the ESMO annual meeting - unveiling insights into cancer analysis, immunotherapy response, and predictive biomarkers at ESMO 2023 SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics an...
Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting
- Lunit's 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeu...
Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening
* Lunit's collaborative study supports AI as a viable alternative to one human reader inEurope's double reading system - published in The Lancet Digital Health SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagno...
Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening
- Lunit's collaborative study supports AI as a viable alternative to one human reader inEurope's double reading system - published in The Lancet Digital Health SEOUL, South Korea, Sept. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnosti...
Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment - to be presented at WCLC 2023
- A collaborative study demonstrates that AI analysis of Tertiary Lymphoid Structures (TLS) in tumors can predict treatment response in non-small cell lung cancer patients SEOUL, South Korea, Aug. 21, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for canc...
Lunit Presents Groundbreaking Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer
- Collaborative study with NCCHE shows that AI analysis of HER2 expression and the tumor microenvironment is linked to treatment response of Pertuzumab+Trastuzumab in colorectal cancer SEOUL, South Korea, Aug. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered soluti...
Lunit Accelerates Expansion Across Middle East by Bringing AI Solution to Dr. Sulaiman Al Habib Medical Group, Middle East's Largest Healthcare Provider
Lunit strengthens presence in the Middle East by supplying AI-powered breast screening solution to Dr. Sulaiman Al Habib Medical Group for the next three years SEOUL, South Korea, July 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnosti...
Lunit Makes Full-Fledged Entry into the Middle East with Participation in 'Saudi Vision 2030' Healthcare Transformation Project
* Lunit's AI-powered cancer screening solutions have been selected for Seha Virtual Hospital's AI evaluation and clinical integration project * Successful validation to be followed by supply contract to assist Saudi Arabia's national cancer and tuberculosis screening program SEOUL, South Korea...
Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination - Published in Radiology
- Recent study conducted by Seoul National University Hospital provides strong evidence that high-accuracy AI model improves radiologists' chest X-ray analysis performance SEOUL, South Korea, July 3, 2023 /PRNewswire/ -- Findings from a recent study demonstrate that medical AI solutions with onl...
